" class="no-js "lang="en-US"> Diagnostic Robotics Closes $45m Series B Funding Round - Medtech Alert
Friday, April 12, 2024

Diagnostic Robotics Closes $45m Series B Funding Round

Diagnostic Robotics, a leading provider of Artificial Intelligence & Care Management solutions for Healthcare plans and providers, today announced the closing of a $45M Series B funding round led by StageOne investors, with participation from Mayo Clinic, thus becoming a Mayo Clinic Platform portfolio company. Technion – Israel Institute of Technology, as well as other existing investors. Strategic angel investor Bradley Bloom, co-founder of Berkshire Partners, participated in this funding round as well.

The new funding will be used to accelerate product development, go-to-market growth, including investment in sales and marketing, and other key hires across the organization.

Diagnostic Robotics experienced significant growth through 2022, tripling its revenues year-over-year since 2020.

Diagnostic Robotics has helped notable customers such as Blue Cross & Blue Shield of Rhode Island, carry out care management programs and leverage AI to home in on predicting patient risk in a precise and impactful way to improve patient outcomes and care paths. Before co-founding Diagnostic Robotics in her current role as CEO, Dr. Kira Radinsky was eBay’s director of data science and chief scientist in Israel. Dr Radinsky is a visiting Professor at the Technion – Israel Institute of Technology and was previously a board member at HSBC as a leading expert in AI.

“Diagnostic Robotics is using the most precise predictive models, leveraging nuanced definitions of risk and shifting focus away from purely risk-based targeting to clinically-actionable targeting to not only change how health plans approach their members, but to drastically improve member clinical care journeys,” said Radinsky.

To date, Diagnostic Robotics has engineered predictive models focused on avoidable emergency room visits, prevention of congestive heart failures deterioration, and serious mental illness, among others. The company continues to engineer additional models and other platforms as part of its expanding product offering.

“We are incredibly excited to be partnering with Kira and the team as they expand and change the way health plans address risk, while helping to drive immensely improved care management for members,” added Yossi Vinitski, of StageOne Ventures.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more